| Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection (NCT02053181) | Actelion | 2012-08-01 |
| Multi-Centre Trial of Fresh vs. Frozen-and-Thawed FMT for Recurrent CDI (NCT01398969) | McMaster University | 2012-07-01 |
| Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) (NCT01597505) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-05-16 |
| A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) (NCT01513239) | Merck Sharp & Dohme LLC | 2012-02-01 |
| Descriptive Epidemiology of Clostridium Difficile Infection in Hospitalized Adult Patients in the Asia Pacific Region (NCT01560832) | Yonsei University | 2011-12-01 |
| A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (NCT01241552) | Merck Sharp & Dohme LLC | 2011-10-10 |
| Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection (NCT02086916) | Barts & The London NHS Trust | 2011-10-01 |
| Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection (NCT01259726) | Shire | 2011-06-27 |
| Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children (NCT01295918) | St Marina University Hospital, Varna, Bulgaria | 2011-02-01 |
| Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD) (NCT01222702) | Actelion | 2011-01-25 |
| An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 (NCT01296386) | Valneva Austria GmbH | 2010-12-01 |
| Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults (NCT01230957) | Sanofi Pasteur, a Sanofi Company | 2010-10-01 |
| Study of CB-183,315 in Participants With Clostridium Difficile Infection (NCT01085591) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2010-04-01 |
| Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections (NCT01077245) | Osel, Inc. | 2010-02-01 |
| Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection (NCT01372943) | Queen's University | 2010-01-01 |
| Clostridium Difficile Infection: the First Report in Southeast Asia by 2010 Nationwide Study (NCT02327520) | King Chulalongkorn Memorial Hospital | 2010-01-01 |
| Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection (NCT00772343) | Sanofi Pasteur, a Sanofi Company | 2009-02-01 |
| Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled Trial (NCT00563186) | University of Calgary | 2007-06-01 |
| Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity (NCT00772954) | Sanofi | 2006-03-01 |